MBX Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MBX Biosciences Inc (MBX)
MBX Biosciences Inc stock price live, this page displays NASDAQ MBX stock exchange data. View the MBX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MBX Biosciences Inc real time stock price chart below.
What Is the MBX Biosciences Inc Stock Price Today?
The MBX Biosciences Inc stock price today is 66.01.
What Is the Stock Symbol for MBX Biosciences Inc?
The stock symbol for MBX Biosciences Inc is "MBX."
What Stock Exchange Does MBX Biosciences Inc Trade On?
MBX Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is MBX Biosciences Inc a Good Stock to Buy?
Determining whether MBX Biosciences Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MBX quote. (ISIN: US55287L1017)
What Is the MBX Biosciences Inc Stock Price Today?
The MBX Biosciences Inc stock price today is 66.01.
What Is the Stock Symbol for MBX Biosciences Inc?
The stock symbol for MBX Biosciences Inc is "MBX."
What Stock Exchange Does MBX Biosciences Inc Trade On?
MBX Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is MBX Biosciences Inc a Good Stock to Buy?
Determining whether MBX Biosciences Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MBX quote. (ISIN: US55287L1017)
Fair Value
An estimate of a MBX Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
65.11
68.49
52 wk Range
9.63
72.64
MBX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a MBX Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
65.1168.49
52 wk Range
9.6372.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MBX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a MBX Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
88.40
Upside
+33.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
MBX Biosciences receives Investment Bank Analyst Rating Update- Investing.com
Pro
- MBX Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro - MBX Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Mbx Biosciences stock hits all-time high of 69.5 USD- Investing.com
MBX Biosciences receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 88.40
(+33.92% Upside)
Earnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.78 / --
Revenue / Forecast
-- / --
Compare MBX to Peers and Sector
Metrics to compare | MBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.5x | −0.8x | −0.4x | |
PEG Ratio | −1.85 | −0.20 | 0.00 | |
Price/Book | 7.8x | 2.6x | 2.6x | |
Price / LTM Sales | - | 2.4x | 3.1x | |
Upside (Analyst Target) | 33.3% | 75.9% | 47.5% | |
Fair Value Upside | Unlock | 3.8% | 5.9% | Unlock |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the MBX Biosciences (MBX) Stock Price Today?
The MBX Biosciences stock price today is 66.01 USD.
What Stock Exchange Does MBX Biosciences Trade On?
MBX Biosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MBX Biosciences?
The stock symbol for MBX Biosciences is "MBX."
What Is the MBX Biosciences Market Cap?
As of today, MBX Biosciences market cap is 3.18B USD.
What Is MBX Biosciences's Earnings Per Share (TTM)?
The MBX Biosciences EPS (TTM) is -2.41.
When Is the Next MBX Biosciences Earnings Date?
MBX Biosciences will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is MBX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has MBX Biosciences Stock Split?
MBX Biosciences has split 0 times.
How Many Employees Does MBX Biosciences Have?
MBX Biosciences has 63 employees.
What is the current trading status of MBX Biosciences (MBX)?
As of Aug 12, 2026, MBX Biosciences (MBX) is trading at a price of 66.01 USD, with a previous close of 66.01 USD. The stock has fluctuated within a day range of 65.11 USD to 68.49 USD, while its 52-week range spans from 9.63 USD to 72.64 USD.
What Is MBX Biosciences (MBX) Price Target According to Analysts?
The average 12-month price target for MBX Biosciences is 88.40 USD, with a high estimate of 121 USD and a low estimate of 70 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +33.92% Upside potential.
What Is the MBX Premarket Price?
MBX's last pre-market stock price is 66.11 USD. The pre-market share volume is 400.00, and the stock has decreased by 0.10, or 0.15%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.